4//SEC Filing
Flex Pharma, Inc. 4
Accession 0001615219-16-000206
$SLRXCIK 0001615219operating
Filed
Jun 16, 8:00 PM ET
Accepted
Jun 17, 3:22 PM ET
Size
9.1 KB
Accession
0001615219-16-000206
Insider Transaction Report
Form 4
Westphal Christoph H
DirectorPresident and CEO10% Owner
Transactions
- Purchase
Common Stock
2016-06-16$11.10/sh+2,900$32,190→ 3,198,461 total(indirect: See notes) - Purchase
Common Stock
2016-06-15$11.24/sh+2,900$32,596→ 3,195,561 total(indirect: See notes)
Holdings
- 3,925,248
Common Stock
Footnotes (5)
- [F1]The price in Column 4 is a weighted average purchase price. The prices actually received ranged from $11.15 to $11.30. The reporting person will provide to the Issuer, any security holder of the Issuer, or the SEC staff, upon request, information regarding the number of shares purchased at each price within the range.
- [F2]On June 15, 2016, Longwood Fund III, L.P. ("Longwood Fund III") purchased 2,900 shares of common stock of the Issuer (the "Common Shares"). Following such purchase, Longwood Fund III owned 498,297 Common Shares and Longwood Fund II, L.P. ("Longwood Fund II") owned 2,697,264 Common Shares.
- [F3]Longwood Fund II GP, LLC is the ultimate General Partner of Longwood Fund II and Longwood Fund III GP, LLC is the ultimate General Partner of Longwood Fund III. Christoph Westphal, M.D., Ph.D., Richard Aldrich and Michelle Dipp, M.D., Ph.D. (collectively, the "Managers") are managers of Longwood Fund II GP, LLC and Longwood Fund III GP, LLC, and, as such, may be deemed to have shared voting and dispositive power with respect to the Issuer's securities held by Longwood Fund II and Longwood Fund III (the "Longwood Shares"). Each of the Managers disclaims beneficial ownership of the Longwood Shares, except to the extent of their respective pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of the shares for purposes of Section 16 or for any other purpose.
- [F4]The price in Column 4 is a weighted average purchase price. The prices actually received ranged from $10.98 to $11.34. The reporting person will provide to the Issuer, any security holder of the Issuer, or the SEC staff, upon request, information regarding the number of shares purchased at each price within the range.
- [F5]On June 16, 2016, Longwood Fund III purchased 2,900 Common Shares. Following such purchase, Longwood Fund III owned 501,197 Common Shares and Longwood Fund II owned 2,697,264 Common Shares.
Documents
Issuer
Flex Pharma, Inc.
CIK 0001615219
Entity typeoperating
IncorporatedDE
Related Parties
1- filerCIK 0001615219
Filing Metadata
- Form type
- 4
- Filed
- Jun 16, 8:00 PM ET
- Accepted
- Jun 17, 3:22 PM ET
- Size
- 9.1 KB